These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 30572079)
1. Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art review. Breitsamer M; Winter G Int J Pharm; 2019 Feb; 557():1-8. PubMed ID: 30572079 [TBL] [Abstract][Full Text] [Related]
2. Needle-Free Injection of Vesicular Phospholipid Gels-A Novel Approach to Overcome an Administration Hurdle for Semisolid Depot Systems. Breitsamer M; Winter G J Pharm Sci; 2017 Apr; 106(4):968-972. PubMed ID: 28041969 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes. Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908 [TBL] [Abstract][Full Text] [Related]
4. Growth factor release by vesicular phospholipid gels: in-vitro results and application for rotator cuff repair in a rat model. Buchmann S; Sandmann GH; Walz L; Reichel T; Beitzel K; Wexel G; Tian W; Battmann A; Vogt S; Winter G; Imhoff AB BMC Musculoskelet Disord; 2015 Apr; 16():82. PubMed ID: 25888096 [TBL] [Abstract][Full Text] [Related]
5. Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma. Qi N; Cai C; Zhang W; Niu Y; Yang J; Wang L; Tian B; Liu X; Lin X; Zhang Y; Zhang Y; He H; Chen K; Tang X Int J Pharm; 2014 Sep; 472(1-2):48-55. PubMed ID: 24914829 [TBL] [Abstract][Full Text] [Related]
6. Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: development and in vitro evaluation. Tian W; Schulze S; Brandl M; Winter G J Control Release; 2010 Mar; 142(3):319-25. PubMed ID: 19925833 [TBL] [Abstract][Full Text] [Related]
7. Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics. Zhong Y; Chen L; Zhang Y; Li W; Sun X; Gong T; Zhang Z Pharmazie; 2013 Oct; 68(10):811-5. PubMed ID: 24273885 [TBL] [Abstract][Full Text] [Related]
9. Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems? Breitsamer M; Stulz A; Heerklotz HH; Winter G Eur J Pharm Biopharm; 2019 Sep; 142():61-69. PubMed ID: 31195130 [TBL] [Abstract][Full Text] [Related]
10. Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix. Grohganz H; Tho I; Brandl M Eur J Pharm Biopharm; 2005 Apr; 59(3):439-48. PubMed ID: 15760724 [TBL] [Abstract][Full Text] [Related]
11. Sterilization stability of vesicular phospholipid gels loaded with cytarabine for brain implant. Qi N; Tang X; Lin X; Gu P; Cai C; Xu H; He H; Zhang Y Int J Pharm; 2012 May; 427(2):234-41. PubMed ID: 22349049 [TBL] [Abstract][Full Text] [Related]
12. Steam sterilisation of vesicular phospholipid gels. Tardi C; Drechsler M; Bauer KH; Brandl M Int J Pharm; 2001 Apr; 217(1-2):161-72. PubMed ID: 11292552 [TBL] [Abstract][Full Text] [Related]
14. Cationic/Anionic Polyelectrolyte (PLL/PGA) Coated Vesicular Phospholipid Gels (VPGs) Loaded with Cytarabine for Sustained Release and Anti-glioma Effects. Qi N; Zhang Y; Tang X; Li A Drug Des Devel Ther; 2020; 14():1825-1836. PubMed ID: 32494124 [TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Kaiser N; Kimpfler A; Massing U; Burger AM; Fiebig HH; Brandl M; Schubert R Int J Pharm; 2003 Apr; 256(1-2):123-31. PubMed ID: 12695018 [TBL] [Abstract][Full Text] [Related]
16. Development and optimization of a new processing approach for manufacturing topical liposomes-in-hydrogel drug formulations by dual asymmetric centrifugation. Ingebrigtsen SG; Škalko-Basnet N; Holsæter AM Drug Dev Ind Pharm; 2016 Sep; 42(9):1375-83. PubMed ID: 26710826 [TBL] [Abstract][Full Text] [Related]
17. Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers. Jebastin K; Narayanasamy D J Liposome Res; 2023 Mar; 33(1):1-33. PubMed ID: 35543241 [TBL] [Abstract][Full Text] [Related]
18. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. Ye Q; Asherman J; Stevenson M; Brownson E; Katre NV J Control Release; 2000 Feb; 64(1-3):155-66. PubMed ID: 10640654 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Angst MS; Drover DR Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293 [TBL] [Abstract][Full Text] [Related]
20. The Advances in Phospholipids-Based Phase Separation Gels for the Sustained Release of Peptides, Proteins, and Chemotherapeutics. Dong J; Zhou X; Li Q; Zheng R; Chen J; Liu Y; Tong X; Wan Z; Gong T Pharmaceutics; 2024 Jun; 16(7):. PubMed ID: 39065572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]